SCHEMBL791368

SCHEMBL791368

CON1CCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL609536 0.96
SCHEMBL529229 0.92
SCHEMBL442896 0.89
Methane SCHEMBL28834058 0.89
Hydrochloric Acid SCHEMBL317366 0.89
SCHEMBL14589063 0.89
Hydrochloric Acid SCHEMBL6810610 0.86
SCHEMBL11231100 0.84
SCHEMBL7096785 0.84
SCHEMBL22996223 0.77 HSD11B1 (0.36)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 211 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4426683-B1 BENZODIAZEPINE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE GABA A GAMMA1 RECEPTOR HOFFMANN LA ROCHE (CH) 2026-04-01 EP claimed
US-20260070912-A1 BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM HOFFMANN-LA ROCHE INC. (US) 2026-03-12 US claimed
US-20250388586-A1 NEW BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM HOFFMANN LA ROCHE (US) 2025-12-25 US claimed
WO-2024092185-A1 ACYL SULFONAMIDE COMPOUNDS AS INHIBITORS OF POLYOMAVIRUS VIA NOVA THERAPEUTICS, INC. (US) 2024-05-02 WO claimed
US-20240124489-A1 SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2024-04-18 US claimed
CN-111295382-B Bridged bicyclic compounds as farnesyl ester X receptor modulators 百时美施贵宝公司 2024-02-02 CN claimed
EP-3814329-B1 NOVEL PYRIDINE AND PYRAZINE COMPOUNDS AS INHIBITORS OF CANNABINOID RECEPTOR 2 HOFFMANN LA ROCHE (CH) 2024-01-17 EP claimed
CN-114126713-B Substituted benzimidazolone compounds 百时美施贵宝公司 2023-12-08 CN claimed
WO-2023102231-A1 5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND METHODS OF USING THE SAME RGENTA THERAPEUTICS, INC. (US) 2023-06-08 WO claimed
US-11655243-B2 Pyridine and pyrazine derivatives as preferential cannabinoid 2 agonists HOFFMANN-LA ROCHE INC. (US) 2023-05-23 US claimed
US-9975900-B2 Substituted imidazo[1,2-α]pyrazines for treating spinal muscular atrophy HOFFMANN-LA ROCHE INC. (US) 2018-05-22 US claimed
US-20170197969-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY HOFFMANN-LA ROCHE INC. (US) 2017-07-13 US claimed
EP-3126349-A1 5,6-DISUBSTITUTED PYRIDINE-2-CARBOXAMIDES AS CANNABINOID RECEPTOR AGONISTS F. Hoffmann-La Roche AG (CH) 2017-02-08 EP claimed
US-20160376237-A1 NOVEL PYRIDINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2016-12-29 US claimed
EP-2776442-B1 [1, 2, 3]TRIAZOLO [4, 5 -D]PYRIMIDINE DERIVATIVES AS AGONISTS OF THE CANNABINOID RECEPTOR 2 HOFFMANN LA ROCHE (CH) 2015-10-21 EP claimed
WO-2015150438-A1 5,6-DISUBSTITUTED PYRIDINE-2-CARBOXAMIDES AS CANNABINOID RECEPTOR AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2015-10-08 WO claimed
EP-2776442-A1 [1, 2, 3]TRIAZOLO [4, 5 -D]PYRIMIDINE DERIVATIVES AS AGONISTS OF THE CANNABINOID RECEPTOR 2 F.HOFFMANN-LA ROCHE AG (CH) 2014-09-17 EP claimed
US-8741906-B2 [1,2,3]triazolo[4,5-D]pyrimidine derivatives HOFFMANN-LA ROCHE INC. (US) 2014-06-03 US claimed
WO-2013068306-A1 [1, 2, 3] TRIAZOLO [4, 5 -D] PYRIMIDINE DERIVATIVES AS AGONISTS OF THE CANNABINOID RECEPTOR 2 F. HOFFMANN-LA ROCHE AG (CH) 2013-05-16 WO claimed
US-20130116236-A1 NOVEL [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2013-05-09 US claimed